Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices 38095 

Proposed Project 

National Hospital Care Survey 

(NHCS) (OMB Control No. 0920–0212, 

Exp. 03/31/2022)—Revision—National 

Center for Health Statistics (NCHS), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

Section 306 of the Public Health 

Service (PHS) Act (42 U.S.C. 242k), as 

amended, authorizes that the Secretary 

of Health and Human Services (DHHS), 

acting through NCHS, shall collect 

statistics on the extent and nature of 

illness and disability of the population 

of the United States. This three-year 

clearance request for National Hospital 

Care Survey (NHCS) includes the 

collection of all inpatient and 

ambulatory Uniform Bill–04 (UB–04) 

claims data or electronic health record 

(EHR) data, as well as the collection of 

hospital-level information via a 

questionnaire from a sample of 608 

hospitals. 

The National Ambulatory Medical 

Care Survey (NAMCS) was conducted 

intermittently from 1973 through 1985, 

and annually since 1989. The survey is 

conducted under authority of Section 

306 of the Public Health Service Act (42 

U.S.C. 242k). The National Hospital 

Discharge Survey (NHDS) (OMB No. 

0920–0212, Exp. Date 01/31/2019), 

conducted continuously between 1965 

and 2010, was the Nation’s principal 

source of data on inpatient utilization of 

short-stay, non-institutional, nonFederal hospitals, and was the principal 

source of nationally representative 

estimates on the characteristics of 

inpatients including lengths of stay, 

diagnoses, surgical and non-surgical 

procedures, and patterns of use of care 

in hospitals in various regions of the 

country. In 2011, NHDS was granted 

approval by OMB to expand its content 

and to change its name to the National 

Hospital Care Survey (NHCS). 

In May 2011, recruitment of sampled 

hospitals for the NHCS began. Hospitals 

in the NHCS are asked to provide data 

on all inpatients from their UB–04 

administrative claims, or EHRs. 

Hospital-level characteristics and data 

on the impact of COVID–19 on the 

hospital are collected through an 

Annual Hospital Interview. NHCS will 

continue to provide the same national 

health-care statistics on hospitals that 

NHDS provided. Additionally, NHCS 

collects more information at the hospital 

level (e.g., volume of care provided by 

the hospital), which allow for analyses 

on the effect of hospital characteristics 

on the quality of care provided. NHCS 

data collected from UB–04 

administrative claims and EHRs include 

all inpatient discharges, not just a 

sample. The confidential collection of 

personally identifiable information 

allows NCHS to link episodes of care 

provided to the same patient in the ED 

and/or OPD and as an inpatient, as well 

as link patients to the National Death 

Index (NDI) to measure post-discharge 

mortality, and Medicare and Medicaid 

data to leverage comorbidities. The 

availability of patient identifiers also 

makes analysis on hospital readmissions 

possible. This comprehensive collection 

of data makes future opportunities for 

surveillance possible, including 

analyzing trends and incidence of 

opioid misuse, acute myocardial 

infarction, heart failure and stroke, as 

well as trends and point prevalence of 

health care acquired infections and 

antimicrobial use. 

Beginning in 2013, in addition to 

inpatient hospital data, hospitals 

participating in NHCS were asked to 

provide data on the utilization of health 

care services in their ambulatory 

settings (e.g., EDs and OPDs). Due to 

low response rates and high level of 

missing data, OPD data were not 

collected in the last approval period 

(2019, 2020 and 2021). Collection of 

OPD may resume in future years. 

Data collected through NHCS are 

essential for evaluating the health status 

of the population, for the planning of 

programs and policy to improve health 

care delivery systems of the Nation, for 

studying morbidity trends, and for 

research activities in the health field. 

There are no changes to the data 

collection survey. The only change is to 

the burden hours due to the increase of 

the sample size. The new total 

annualized burden is 7,184 hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Hospital DHIM or DHIT .. Initial Hospital Intake Questionnaire .................... 150 1 1 136 

Hospital CEO/CFO ........ Recruitment Survey Presentation ........................ 150 1 1 136 

Hospital DHIM or DHIT .. Prepare and transmit UB–04 or State File for Inpatient and Ambulatory (monthly).408 12 1 4,896 

Hospital DHIM or DHIT .. Prepare and transmit EHR for Inpatient and Ambulatory (quarterly).200 4 1 800 

Hospital CEO/CFO ........ Annual Hospital Interview .................................... 608 1 2 1,216 

Total ........................ .............................................................................. ........................ ........................ ........................ 7,184 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–15229 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Multi-Agency Informational Meetings 

To Discuss Reporting Requirements 

for Entities; Public Webinars 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS) 

ACTION: Notice of public webinars. 

SUMMARY: The HHS/CDC’s Division of 

Select Agents and Toxins (DSAT) and 

the U.S. Department of Agriculture/ 

Animal and Plant Health Inspection 

Service (APHIS)’s Division of 

Agricultural Select Agents and Toxins 

(DASAT) are jointly charged with the 

regulation of the possession, use and 

transfer of biological agents and toxins 

that have the potential to pose a severe 

threat to public, animal or plant health 


lotter on DSK11XQN23PROD with NOTICES1
38096 Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices 

or to animal or plant products (select 

agents and toxins). This joint effort 

constitutes the Federal Select Agent 

Program. Due to the continuing 

pandemic and concerns for the safety of 

our workshop attendees and employees, 

DSAT replaced in-person workshops 

with webinars. The purpose of the 

webinars is to provide guidance on 

completing APHIS/CDC Form 2 

(Request to Transfer Select Agents and 

Toxins), APHIS/CDC Form 3 (Report of 

a Release/Loss/Theft), and APHIS/CDC 

Form 4 (Reporting the Identification of 

a Select Agent or Toxin) (APHIS/CDC 

Forms 2–4) for interested individuals. 

Two sessions covering the same agenda 

will be held to provide two 

opportunities for interested individuals 

to participate. 

DATES: The webinars will be held 

October 6, 2021 from 10 a.m. to 12:30 

p.m. (EDT) and November 3, 2021 from 

1:30 p.m. to 4:00 p.m. (EDT). 

Registration instructions are found on 

the website, https://

www.selectagents.gov. 

ADDRESSES: The webinars will be 

conducted from the Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Atlanta, Georgia 30329. 

FOR FURTHER INFORMATION CONTACT: 

CDC: Samuel S. Edwin, Ph.D., Director, 

DSAT, Center for Preparedness and 

Response, CDC, 1600 Clifton Road NE, 

MS H–21–7, Atlanta, Georgia 30329. 

Telephone: (404) 718–2000; email: 

lrsat@cdc.gov. APHIS: Jack Taniewski, 

DVM, Director, DASAT, APHIS, 4700 

River Road, Unit 2, Riverdale, MD 

20737. Telephone: (301) 851–2070; 

email: DASAT@usda.gov. 

SUPPLEMENTARY INFORMATION: The two 

public webinar sessions covering the 

same content, scheduled for 

Wednesday, October 6, 2021 and 

Wednesday, November 3, 2021, are 

opportunities for interested individuals 

to obtain guidance on completing the 

APHIS/CDC Forms 2–4 and reporting 

requirements related to the select agent 

and toxin regulations (7 CFR part 331, 

9 CFR part 121 and 42 CFR part 73). For 

individuals not able to attend the 

webinars, the information will be 

available under the training section at 

http://www.selectagents.gov. 

Representatives from the Federal 

Select Agent Program will be present 

during the webinars followed by 

question and answer session to address 

questions and concerns from the 

webinar participants. 

Participants who want to participate 

in the webinar should complete their 

registration online by September 18, 

2021. The registration instructions are 

located on this website: http://

www.selectagents.gov. 

Dated: July 14, 2021. 

Sandra Cashman, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2021–15305 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. 

Name of Committee: Safety and 

Occupational Health Study Section 

(SOHSS), National Institute for 

Occupational Safety and Health 

(NIOSH). 

Dates: October 20–21, 2021. 

Time: 11:00 a.m.–5:00 p.m., EDT. 

Place: Teleconference. 

Agenda: The meeting will convene to 

address matters related to the conduct of 

Study Section business and for the 

study section to consider safety and 

occupational health-related grant 

applications. 

For Further Information Contact: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, NIOSH, CDC, 1095 

Willowdale Road, Morgantown, WV 

26506; Telephone: (304) 285–5951; 

Email: mgoldcamp@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–15246 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–21DC] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled National 

Syringe Services Program (SSP) 

Evaluation to the Office of Management 

and Budget (OMB) for review and 

approval. CDC previously published a 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ notice on February 

25, 2021 to obtain comments from the 

public and affected agencies. CDC 

received three public comments related 

to the previous notice. This notice 

serves to allow an additional 30 days for 

public and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 


lotter on DSK11XQN23PROD with NOTICES1